Indication
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
8 clinical trials
8 products
12 drugs
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic AlterationsStatus: Recruiting, Estimated PCD: 2024-09-30
Product
EnsartinibClinical trial
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent TumorsStatus: Active (not recruiting), Estimated PCD: 2013-01-19
Product
melphalanDrug
busulfanClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair GenesStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Product
OlaparibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK FusionsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
LarotrectinibProduct
TopotecanDrug
FilgrastimClinical trial
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With IpilimumabStatus: Completed, Estimated PCD: 2021-09-30
Product
IpilimumabDrug
T-VECClinical trial
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell TumorsStatus: Active (not recruiting), Estimated PCD: 2015-08-01
Drug
vinca alkaloidsDrug
doxorubicinDrug
cyclophosphamideDrug
ifosfamideDrug
etoposideDrug
temozolomideDrug
temsirolimusDrug
bevacizumabDrug
sorafenibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 AlterationsStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Product
ErdafitinibClinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF ComplexStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Product
Tazemetostat